683 Capital Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.92M Buy
+156,000
New +$7.28M 0.41% 54
2024
Q3
Sell
-242,000
Closed -$28.7M 151
2024
Q2
$28.7M Buy
+242,000
New +$30.6M 2.17% 11
2023
Q4
Sell
-15,000
Closed -$1.55M 269
2023
Q3
$1.55M Sell
15,000
-45,000
-75% -$5.02M 0.12% 90
2023
Q2
$7.29M Hold
60,000
0.52% 54
2023
Q1
$9.21M Buy
+60,000
New +$9.9M 0.69% 43

Other funds holding MRNA

683 Capital Management's MRNA Position: Q3 2024 in Review

683 Capital Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 28,629 shares — an estimated $2.63M sold.

683 Capital Management first reported a position in MRNA in Q2 2024 and held it in 1 quarter. The position peaked at $3.4M in Q2 2024. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • 683 Capital Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • 683 Capital Management sold 28,629 Moderna shares in Q3 2024, an estimated $2.63M.
  • 683 Capital Management first reported a position in Moderna in Q2 2024 and held it in 1 quarter.
  • 683 Capital Management's Moderna position peaked at $3.4M in Q2 2024.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on 683 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.